Sign In
Buy MCRB
$4.83
+0.0500 (+1.05%)
At Close: Jul 31, 2026
Seres Jumps On Data, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:MCRB)
04:22pm, Tuesday, 11'th Aug 2020
Seres Therapeutics stock jumps on positive topline data. Humanigen expands Lenzilumab study in Brazil.
Seres Therapeutics (NASDAQ:MCRB) Upgraded by ValuEngine to Buy
01:36am, Tuesday, 11'th Aug 2020
Seres Therapeutics (NASDAQ:MCRB) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued on Tuesday, ValuEngine reports. Several othe
Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
12:00am, Tuesday, 11'th Aug 2020
Seres Therapeutics, Inc. today announced that it is commencing an underwritten registered public offering of 8,000,000 shares of its common stock.
Chardan Capital Sticks to Its Buy Rating for Seres Therapeutics (MCRB) - Markets
08:55pm, Monday, 10'th Aug 2020
Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Seres Therapeutics (MCRB – Research Report) today and set a
Juros reais negativos: como você deve investir com uma inflação acima do CDI
08:02pm, Monday, 10'th Aug 2020
Nova realidade deve levar investidor a buscar mais risco na alocação de renda fixa, ainda que reserva de emergência seja penalizada
Why Seres Therapeutics Stock Skyrocketed 350% Today
07:52pm, Monday, 10'th Aug 2020
Shares of Seres Therapeutics (NASDAQ: MCRB) soared on Monday after the biotech company announced promising results from a phase 3 study of its experimental therapy for colon infections. Seres said t
Seres Therapeutics Stock Scales Nasdaq on Positive Drug Data
05:39pm, Monday, 10'th Aug 2020
The stock hit a four-year high earlier in the day
Return On Capital Employed Overview: Seres Therapeutics
03:34pm, Monday, 10'th Aug 2020
During Q2, Seres Therapeutics (NASDAQ: MCRB) reported sales totaled $6.04 million. Despite a 4.33% in earnings, the company posted a loss of $20.55 million. In Q1, Seres Therapeutics brought in $8.19
This Tiny Biotech's Shares Quadruple After Late-Stage Drug Tests Succeed
02:39pm, Monday, 10'th Aug 2020
Seres Therapeutics early Monday announced Phase 3 success with its study of a treatment for a potentially fatal colon disease treatment, sending MCRB stock quadrupling in early trading.
Seres Therapeutics stock rockets nearly fourfold after positive Phase 3 data on treatment for colon infections
12:27pm, Monday, 10'th Aug 2020
Shares of Seres Therapeutics Inc. undefined rocketed nearly fourfold (up 270%) on heavy volume in premarket trading Monday, after the microbiome therapeutics...
Seres Therapeutics stock rockets nearly fourfold after positive Phase 3 data on treatment for colon infections
12:27pm, Monday, 10'th Aug 2020
Shares of Seres Therapeutics Inc. rocketed nearly fourfold (up 270%) on heavy volume in premarket trading Monday, after the microbiome therapeutics company reported upbeat results of a Phase 3 trial
Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection
10:30am, Monday, 10'th Aug 2020
SER-109 met Phase 3 primary endpoint, showing highly statistically significant 30.2% absolute reduction in the rate of C. diff infection recurrence.
Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection
12:00am, Monday, 10'th Aug 2020
SER-109 met Phase 3 primary endpoint, showing highly statistically significant 30.2% absolute reduction in the rate of C. diff infection recurrence.
Banco de Chile (BCH) Q2 2020 Results - Earnings Call Transcript
11:29pm, Friday, 07'th Aug 2020
Banco de Chile (NYSE:BCH) Q2 2020 Earnings Conference Call August 07, 2020, 12:30 PM ET Company Participants Rodrigo Aravena - Chief Economist and Senior Vice President of Institutional Relations Pabl
Do Options Traders Know Something About Seres Therapeutics (MCRB) Stock We Don't?
12:55pm, Friday, 07'th Aug 2020
Investors need to pay close attention to Seres Therapeutics (MCRB) stock based on the movements in the options market lately.
